T-cell subset distribution in HIV-1-infected patients after 12 years of treatment-induced viremic suppression

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 3, 2012, Pages 270-278

  Rönsholt, Frederikke F ^a   Ullum, Henrik ^a   Katzenstein, Terese L ^a   Gerstoft, Jan ^a   Ostrowski, Sisse R ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Antiretroviral therapy; FACS; HIV 1; Immune reconstitution; T lymphocyte subsets; Viral load

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIREMIA; CASE CONTROL STUDY; CD4 CD8 RATIO; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED; VIRUS LOAD;

CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CROSS-SECTIONAL STUDIES; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIREMIA;

EID: 84861114268     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825e7ac1     Document Type: Article

References (68)

1. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
2. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV Cohort Study. Clin Infect Dis. 2011;53: 1130-1139.
3. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23: 2337-2345.
4. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2512.
5. Guihot A, Tubiana R, Breton G, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS. 2010;24:614-617.
6. Hughes R, Sterne J, Walsh J, et al. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med. 2011;12:583-593.
7. Li T, Wu N, Dai Y, et al. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis. 2011;53:944-951.
8. Kolte L, Dreves AM, Ersboll AK, et al. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2002;185:1578-1585.
9. Appay V, van Lier RA, Sallusto F, et al. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A. 2008;73:975-983.
10. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763.
11. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893-900.
12. Chomont N, DaFonseca S, Vandergeeten C, et al. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS. 2011;6:30-36.
13. Appay V, Nixon DF, Donahoe SM, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000;192:63-75.
14. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature. 2001;410:980-987.
15. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410:106-111.
16. Yue FY, Kovacs CM, Dimayuga RC, et al. HIV-1-specific memory CD4+ T cells are phenotypically less mature than cytomegalovirus-specific memory CD4+ T cells. J Immunol. 2004;172:2476-2486.
17. Pohling J, Zipperlen K, Hollett NA, et al. Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy. BMC Infect Dis. 2010;10:129.
18. Rehr M, Cahenzli J, Haas A, et al. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol. 2008;82:3391-3404.
19. Harari A, Petitpierre S, Vallelian F, et al. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antire-troviral therapy. Blood. 2004;103:966-972.
20. Mildvan D, Bosch RJ, Kim RS, et al. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004;189:1811-1820.
21. Hunt PW. T cell activation is associated with lower CD4+ cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
22. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942-947.
23. Tilling R, Kinloch S, Goh LE, et al. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS. 2002;16:589-596.
24. Anthony KB, Yoder C, Metcalf JA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretro-viral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr. 2003;33:125-133.
25. Katzenstein TL, Ullum H, Roge BT, et al. Virological and immunolog-ical profiles among patients with undetectable viral load followed pro-spectively for 24 months. HIV Med. 2003;4:53-61.
26. Ostrowski SR, Katzenstein TL, Thim PT, et al. Low-level viremia and pro-viral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2005;191:348-357.
27. Ostrowski SR, Ullum H, Pedersen BK, et al. 2B4 expression on natural killer cells increases in HIV-1 infected patients followed prospectively during highly active antiretroviral therapy. Clin Exp Immunol. 2005;141:526-533.
28. Ostrowski SR, Katzenstein TL, Pedersen BK, et al. Residual viraemia in HIV-1-infected patients with plasma viral load,or=20 copies/ml is associated with increased blood levels of soluble immune activation markers. Scand J Immunol. 2008;68:652-660.
29. Obel N, Engsig FN, Rasmussen LD, et al. Cohort profile: the Danish HIV Cohort Study. Int J Epidemiol. 2009;38:1202-1206.
30. Chattopadhyay PK, Roederer M. Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease. Cytometry A. 2010;77:614-622.
31. Ostrowski SR. Immune activation in chronic HIV infection. Dan Med Bull. 2010;57:B4122.
32. Bonora S, Nicastri E, Calcagno A, et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol. 2009;81:400-405.
33. Palmisano L, Giuliano M, Nicastri E, et al. Residual viraemia in subjects with chronic HIV infection and viral load, 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS. 2005;19:1843-1847.
34. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003;77:11212-11219.
35. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286: 171-179.
36. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term anti-retroviral treatment. Clin Infect Dis. 2009;48:787-794.
37. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. 2009;48:350-361.
38. Vrisekoop N, van GR, de Boer AB, et al. Restoration of the CD4 T cell compartment after long-term highly active antiretroviral therapy without phenotypical signs of accelerated immunological aging. J Immunol. 2008;181:1573-1581.
39. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-446.
40. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretro-viral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163:2187-2195.
41. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007;370:407-413.
42. Landay A, da Silva BA, King MS, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007;44:749-754.
43. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204:1217-1226.
44. Rose T, Lambotte O, Pallier C, et al. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol. 2009;182:7389-7397.
45. Colle JH, Moreau JL, Fontanet A, et al. Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients-effects of antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;42:277-285.
46. Colle JH, Moreau JL, Fontanet A, et al. CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients-reversal by highly active anti-retroviral therapy (HAART). Clin Exp Immunol. 2006;143:398-403.
47. Camargo JF, Kulkarni H, Agan BK, et al. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression. J Infect Dis. 2009;199:1872-1882.
48. Kimmig S, Przybylski GK, Schmidt CA, et al. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med. 2002;195:789-794.
49. Kohler S, Thiel A. Life after the thymus: CD31+ and CD31-human naive CD+ T-cell subsets. Blood. 2009;113:769-774.
50. Tanaskovic S, Fernandez S, Price P, et al. CD31 (PECAM-1) is a marker of recent thymic emigrants among CD4+ T-cells, but not CD8+ T-cells or gammadelta T-cells, in HIV patients responding to ART. Immunol Cell Biol. 2010;88:321-327.
51. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396: 690-695.
52. Douek DC, Betts MR, Hill BJ, et al. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol. 2001;167:6663-6668.
53. Resino S, Seoane E, Perez A, et al. Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy. BMC Infect Dis. 2006;6:112.
54. Franco JM, Leon-Leal JA, Leal M, et al. CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients. Clin Exp Immunol. 2000;119:493-498.
55. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
56. Papagno L, Spina CA, Marchant A, et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol. 2004;2:E20.
57. Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunction-ality, and clonal turnover. J Exp Med. 2007;204:2473-2485.
58. Nomura LE, Emu B, Hoh R, et al. IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells. AIDS Res Ther. 2006;3:18.
59. Lopez M, Soriano V, Peris-Pertusa A, et al. Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART. AIDS Res Hum Retroviruses. 2011;27:157-165.
60. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-155.
61. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010;7:4-10.
62. Kalayjian RC, Landay A, Pollard RB, et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis. 2003;187:1924-1933.
63. Sansoni P, Vescovini R, Fagnoni F, et al. The immune system in extreme longevity. Exp Gerontol. 2008;43:61-65.
64. Onyema OO, Njemini R, Bautmans I, et al. Cellular aging and senescence characteristics of human T-lymphocytes. Biogerontology. 2012;13:169-181.
65. Olsson J, Wikby A, Johansson B, et al. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121:187-201.
66. Elrefaei M, McElroy MD, Preas CP, et al. Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol. 2004;173:2184-2189.
67. Steel A, John L, Shamji MH, et al. CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy. HIV Med. 2008;9:118-125.
68. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7:235-239.